Fluorescein Novartis

Active material: Fluorescein Sodium
When ATH: S01JA01
CCF: Preparation for fluorescein angiography and Angioscopy in ophthalmology
When CSF: 30.04.01
Manufacturer: NOVARTIS PHARMA AG (Switzerland)

PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING

The solution for the on / in the dark orange color, clear.

[Ring] Sodium hydroxide, water d / and.

5 мл – ампулы бесцветного стекла (10) – пачки картонные.

DESCRIPTION OF ACTIVE SUBSTANCES

Pharmacological action

Means for fluorescein angiography and Angioscopy in ophthalmology. Yellow-green fluorescence of the active substance allows to delimit the area of ​​vascularization from the surrounding tissue to improve visualization.

Pharmacokinetics

–

Testimony

Diagnostic angiography or angioscopy in ophthalmology.

Dosage regimen

Enter the I / O by a special method. Visualization of vessels in the retina and choroidal vessels can be carried out through 9 and 14 minutes after administration.

Side effect

Nausea, headache, gastrointestinal disorders, syncope, vomiting, hives, hypotension, cardiac arrest, bronchospasm, basilar artery ischemia, shock, convulsions, thrombophlebitis at the injection site, в отдельных случаях – летальный исход.

If extravasation occurs severe pain at the injection site, and can be a dull ache in the corresponding limb.

Contraindications

Hypersensitivity Fluorescein.

Pregnancy and lactation

Angiography should be avoided during pregnancy, especially in the I trimester. Safety of fluorescein during pregnancy has not been studied. Fluorescein is excreted in breast milk. Be wary of lactation.

Cautions

It is intended only for I / O administration and diagnostic procedures in ophthalmology.

To apply caution in patients with a history of instructions on allergic reactions, bronchospasm.

You should avoid extravasation during injection. Because of possible skin necrosis extravasation, superficial phlebitis, subcutaneous pellets, toxic optic neuritis at the injection site. When significant extravasation injection should be discontinued.

Drug Interactions

–

Conditions and terms

The Republic of Kazakhstan is not registered.